Skip to content
Briefings are running a touch slower this week while we rebuild the foundations.See roadmap
UK Startups and Innovation
13APR

Tropic Biosciences raises $105m from Norwich

2 min read
17:59UTC

A gene-editing tropical crops company closed an oversubscribed Series C outside the London-Oxford-Cambridge corridor. Temasek and Corteva Catalyst are on the cap table.

← Back to State capital floods in, seed money drainsJump to analysis ↓
TechnologyDeveloping
Key takeaway

A Norwich gene-editing company raised $105m, proving deep-tech capital can reach beyond the Golden Triangle.

Tropic Biosciences, a Norwich-based gene-editing company focused on tropical crops, closed an oversubscribed $105m Series C co-led by Forbion and Corteva Catalyst 1. Temasek, Just Climate, and IQ Capital also participated. The round is one of the few large UK deep-tech raises located outside the London, Oxford, and Cambridge corridor.

Tropic works on gene-editing staple crops (bananas, coffee, rice) for disease resistance and yield improvement. The investor mix reflects the company's position at the intersection of food security and biotechnology: Corteva is a global agricultural sciences company, Temasek is Singapore's sovereign wealth fund with a strong food security mandate, and Just Climate focuses on climate-positive investment.

Norwich's presence in the round is notable. The city hosts the John Innes Centre and the Earlham Institute, two of the UK's strongest plant and genomic science institutions, but the region has not historically attracted venture capital at this scale. Tropic's success suggests that deep-tech companies rooted in genuine research clusters can raise internationally even without a London address, provided the science is strong and the commercial application (food supply resilience) has a clear global buyer.

Deep Analysis

In plain English

Tropic Biosciences is a company based in Norwich that uses gene-editing (not genetic modification in the traditional sense) to develop crop varieties that are more disease-resistant, drought-tolerant, or longer-lasting. It works primarily on tropical crops like bananas and coffee. It raised $105m, meaning investors gave it that money in exchange for a share of the company. Unusually for UK deep tech investment, which clusters heavily around London, Cambridge, and Oxford, this company is in Norwich. Its success demonstrates that significant investment can reach UK tech companies outside the traditional funding hubs.

What could happen next?
  • Opportunity

    Tropic's raise demonstrates that deep-tech companies outside the London-Oxford-Cambridge corridor can attract major international institutional investors, potentially encouraging more regional deep-tech investment.

Sources:The Next Web
Mentions:Tropic Biosciences →Forbion →Corteva Catalyst →Temasek →Spark Capital →Cambridge →Just Climate →John Innes Centre →Wyss Institute →
First Reported In

Update #1 · State capital floods in, seed money drains

The Next Web· 13 Apr 2026
Read original →
Different Perspectives
European limited partners (Plural, Aviva Investors)
European limited partners (Plural, Aviva Investors)
Pan-European fund Plural led Orbital's $50m and Aviva Investors co-anchored the BBB's Lansdowne spinout fund (event ID:3505), demonstrating that Continental and UK institutional capital can fill the growth-stage tier independently, though neither has the scale to compete with US growth funds at the $100m+ band that successive ex-DeepMind rounds will eventually reach.
France (DSIT / GENCI / Institut Pasteur)
France (DSIT / GENCI / Institut Pasteur)
France signed the UK-France Strategic Biomedical Alliance on 29 May, contributing €330,000 a year to researcher mobility and linking GENCI national compute to Isambard-AI; the bilateral format suits Paris because it produces scientific access without requiring EU-framework ratification while the UK-EU science relationship remains unsettled.
US growth investors (NVentures, General Catalyst, Crosspoint Capital)
US growth investors (NVentures, General Catalyst, Crosspoint Capital)
NVentures entering Orbital's cap table for the first time and General Catalyst following on in Geordie's Series A signals US growth investors treating London deeptech as a buy-side opportunity the UK market cannot contest. NVentures gains supply-chain visibility into GPU cooling; General Catalyst gains a frontier security category the RSAC prize has already validated for US enterprise.
UK Government (DSIT / British Business Bank)
UK Government (DSIT / British Business Bank)
The BBB cornerstoned Longwall at the seed floor on 27 May while DSIT signed the UK-France bilateral compute deal the same week, deploying state capital at bottom and research layers simultaneously. Neither instrument addresses the Series B middle the April 2026 mandate expansion could reach but has not.
Australian Department of Defence (AUKUS partner, Rowden Technologies)
Australian Department of Defence (AUKUS partner, Rowden Technologies)
Rowden Technologies holds active AUKUS AI for Acoustics contracts with the UK, US and Australian defence establishments. The NWF's £25m investment in Rowden on 13 May places UK sovereign capital directly into a trilateral programme Australia co-funds; from Canberra's perspective, the NWF cheque increases UK government skin-in-the-game on a programme where Australia has already committed co-development resources.
Temasek (Singapore sovereign co-investor, Isomorphic Series B)
Temasek (Singapore sovereign co-investor, Isomorphic Series B)
Temasek co-invested with the SAIU in Isomorphic's $2.1bn Series B the previous week, treating a majority Alphabet-owned company as a valid sovereign co-investment target. Fractile's round, without a UK sovereign co-investor, reads differently from Singapore's vantage: allied state capital (NATO-IF, In-Q-Tel) is now competing with Asian sovereign funds for early positions in UK deeptech.